China’s Bio-Thera Solutions has reported positive Phase III results for its BAT1706 proposed biosimilar rival to Avastin (bevacizumab).
Bio-Thera Reports Positive Bevacizumab Results
Avastin Rival Is Firm’s Second Biosimilar With Positive Phase III Outcome
China’s Bio-Thera Solutions has reported positive Phase III results for its proposed bevacizumab biosimilar rival to Avastin.
More from Biosimilars
More from Products
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.